

CLAIMS

[1] A medicinal composition for healing, preventing or treating vascular disorders, hypertension, and renal disorders, comprising:

a drug having the effect of inhibiting uric acid uptake via URAT1; and

a pharmaceutically acceptable carrier.

[2] The medicinal composition according to claim 1, wherein the vascular disorders, hypertension, and renal disorders are induced by hyperuricemia.

[3] The medicinal composition according to claim 1 or 2, wherein the drug having the effect of inhibiting uric acid uptake via URAT1 is a URAT1 inhibitor or blocker.

[4] The medicinal composition according to any one of claims 1 to 3, wherein the medicinal composition for healing, preventing or treating vascular disorders, hypertension, and renal disorders is a vascular protective agent.

[5] A method of screening a substance efficacious for healing, preventing or treating vascular disorders, hypertension, and renal disorders, the method comprising using a cell line expressing URAT1 in the presence or absence of a test compound; and assaying the uric acid uptake level.

[6] The method according to claim 4, wherein the cell line expressing URAT1 is a cell line stably expressing URAT1 gene.

[7] The method according to claim 5 or 6, wherein the

uric acid uptake level is assayed with the use of a uric acid uptake solution of cell line expressing URAT1 in the present of a test compound.

[8] A method of screening a substance efficacious for healing, preventing or treating vascular disorders, hypertension, and renal disorders, the method comprising using a cell line expressing URAT1 in the presence or absence of a test compound; and assaying the proliferation ability of the cells.

[9] The method according to claim 8, wherein the proliferation ability of the cells is assayed by measuring the thymidine uptake level by the cells.

[10] A method of screening a substance efficacious for healing, preventing or treating vascular disorders, hypertension, and renal disorders, the method comprising using a cell line expressing URAT1 in the presence or absence of a test compound; and assaying the amount of a monocyte chemotactic factor produced by the cells.

[11] The method according to claim 10, wherein the monocyte chemotactic factor is MCP-1.